yahoo_financeOriginal article
Seaport Therapeutics Says GlyphAllo Shows no Next-Morning Driving Impairment in Phase 1 Trial
Phase 1positiveGlyphAlloPositive
AI Analysis
Summary
Seaport Therapeutics announced that GlyphAllo demonstrated no next-morning driving impairment in a Phase 1 trial, suggesting a favorable safety profile for the candidate drug.
Clinical Trial Data
Phase
1
Primary Endpoint
Met
Outcome Details
GlyphAllo showed no next-morning driving impairment in Phase 1 trial
Importance:5/10
Sentiment:
0.70
Phase 1safetydriving impairmentclinical trial
Related Companies
Read the original article
Published by yahoo_finance on September 9, 2026 11:54 AM